Total Facility Solutions wins contract from Novartis

Published: 14-Sep-2011
Manufacturing Finance

To install hygienic process piping at Vaccines and Diagnostics plant in Holly Springs, NC

Total Facility Solutions, a specialist contractor focused on critical process infrastructure, has been awarded a contract to install hygienic process piping at the Novartis Vaccines and Diagnostics campus in Holly Springs, North Carolina, US.

The order is part of Novartis’ US$36m expansion of its pandemic and seasonal flu production facility, announced last December, which will create 100 new jobs at the Holly Springs development lab and pilot plant.

‘This selection to fabricate and install process piping at Novartis affirms the strength of our model for serving the life science business,’ said Joe Cestari, president of Total Facility Solutions.

‘Having invested heavily in our own North Carolina facility in 2009, we bring the infrastructure, industry expertise and experienced personnel necessary to execute on this project on time, on budget and to specification.’

The project will be operated out of Total Facility Solutions’ Raleigh, NC location, using its 4,000ft2 clean manufacturing space to complete all building work. This plant is equipped with the latest technology for orbital welding and meets stringent market requirements while facilitating just-in-time delivery to the construction site. Bovis Lend Lease and Novartis’ project managers are overseeing the project.

Total Facility Solutions (TFS) provides turnkey facilities contracting services including high-purity piping, gas and chemical systems, ultra-high purity water systems, tool and equipment installation, clean utilities, and electrical services to the semiconductor, electronics, nanotechnology, photovoltaic, life sciences, mission critical, and renewable energy industries.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Containment

Clean environments: meeting modern drug production challenges

Read more
New medicinal therapies are seeing rapid development but face many price pressures and regulatory challenges. George Wiker, VP, M+W Group and Kurt Gilson, VP, Western US, Total Facility Solutions, discuss the impact on facility design

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
  3. Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
  4. Simplifying continuous operations: lowering the barrier to faster development Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it
  5. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Containment

Clean environments: meeting modern drug production challenges

New medicinal therapies are seeing rapid development but face many price pressures and regulatory challenges. George Wiker, VP, M+W Group and Kurt Gilson, VP, Western US, Total Facility Solutions, discuss the impact on facility design
Manufacturing

Total Facility Solutions builds dedicated hygienic fabrication plant

Company will be better positioned to support the high purity piping needs of numerous life science customers
Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Finance

Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach

The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Subscribe now